Southwestern Medical Center investigators have identified a genetic manipulation that increases the development of neurons in the brain during aging...
Scientists have laid bare a novel molecular mechanism responsible for the major depression symptom, anhedonia, the loss of the ability to experience pleasure. The brain circuit involved in this newly elucidated pathway is largely identical between rodents and humans, upping the odds that the findings point toward new therapies for depression and other disorders. Additionally, opinion leaders hailed the study’s inventive methodology, saying it may offer a much sounder approach to testing new antidepressants.
Neuroscientists found that astrocytes may be responsible for the rapid improvement in mood in depressed patients after acute sleep deprivation. This study identified how astrocytes can regulate a neurotransmitter involved in sleep.
Researchers identify a protein that appears to be the target of both antidepressant drugs and electroconvulsive therapy. The experimental results explain how these therapies likely work to relieve depression by stimulating stem cells in the brain to grow and mature.
A new study funded by the NIMH suggests GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the negative side effects of the well known street drug.
A synthetic compound, decynium-22, is able to turn off SERT in the brain, enhancing the effectiveness of SSRIs.
Researchers suggest serotonin metabolism in the pineal gland could play a role in the underlying cause of depression. The findings were based on biochemical changes which were seen to be in association with improvements in depression.
Researchers identify a molecular pathway which accelerates the time taken for antidepressants to work in mouse models.
A common antidepressant proves effective in easing agitation associated with Alzheimer's disease, a new study reports.